Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1783972 | 0.85 | — | — | |
| SCHEMBL1787366 | 0.84 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNAKDM4EALDH1A1MAPT | |
| SCHEMBL12650842 | 0.80 | SMN1; SMN2 (0.43) | SMN1; SMN2LMNAKDM4EALDH1A1MAPT | |
| SCHEMBL1787283 | 0.80 | MAPT (0.45) | SMN1; SMN2LMNAKDM4EALDH1A1MAPT | |
| SCHEMBL20504192 | 0.77 | SMN1; SMN2 (0.40) | SMN1; SMN2LMNAKDM4EALDH1A1MAPT | |
| SCHEMBL12651187 | 0.75 | TSHR (0.43) | SMN1; SMN2LMNAALDH1A1MAPK1CYP3A4 | |
| SCHEMBL18891004 | 0.75 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNAKDM4EALDH1A1MAPT | |
| SCHEMBL12607009 | 0.72 | — | — | |
| SCHEMBL7479270 | 0.69 | KMT2A (0.36) | SMN1; SMN2LMNAKDM4EALDH1A1MAPT | |
| SCHEMBL7479274 | 0.69 | KMT2A (0.36) | SMN1; SMN2LMNAKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273901-B2 | Process of forming a pyrrole compound | Nanyang Technical University (SG) | 2012-09-25 | — | — | US | disclosed |
| US-8273901-B2 | Process of forming a pyrrole compound | Nanyang Technical University (SG) | 2012-09-25 | — | — | US | disclosed |
| US-20110124881-A1 | PROCESS OF FORMING A PYRROLE COMPOUND | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2011-05-26 | — | — | US | disclosed |
| US-20110124881-A1 | PROCESS OF FORMING A PYRROLE COMPOUND | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124881-A1 | PROCESS OF FORMING A PYRROLE COMPOUND | OXER1, OGDH, OPRD1 | SMN1; SMN2 1650/4885LMNA 3028/4885KDM4E 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.